Diabetes
Refine Search
Pharmaceutical
Russia is accelerating its expansion in the pharmaceutical market of Central and South American states by localization of a number of drugs within their territories, according to recent statements by representatives of some leading Russian drugmakers and pharma analysts, reports The Pharma Letter’s local correspondent. 6 April 2021
Pharmaceutical
2020 was a good year for Boehringer Ingelheim, although the effects of the COVID-19 pandemic were omnipresent, said the German family-owned pharma major. 24 March 2021
Pharmaceutical
Novo Nordisk late Monday announced that the US Food and Drug Administration has issued a Refusal to File letter covering the label expansion application for once-weekly semaglutide 2.0mg for the treatment of type 2 diabetes, which was filed on 20 January 2021. 23 March 2021
Biotechnology
The odds for and against betting on Provention Bio’s teplizumab, which is being studied in the prevention of type 1 diabetes (T1D) among at-risk patients, have been assessed. 22 March 2021
Pharmaceutical
Shares in diabetes giant Novo Nordisk fell back 4% on Thursday, after its blockbuster Ozempic (semaglutide) was outshone in a head-to-head study. 5 March 2021
Pharmaceutical
German science and technology company Merck KGaA has reported impressive sales and earnings figures in its latest quarterly and full-year 2020 financial results. 4 March 2021
Pharmaceutical
Danish diabetes care giant Novo Nordisk last month released impressive data from its Phase IIIa STEP1 trial for semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in a bid to strengthen its position as the market leader in obesity. 4 March 2021
Biosimilars
Russian drugmaker Geropharm plans to become one of the leading players in the domestic insulins market within the next several years, with the possible launch of a biosimilar of ultra-long-acting insulin, produced by the Danish diabetes care giant Novo Nordisk, as well as a further expansion of its portfolio. 2 March 2021
Pharmaceutical
Agreement has been reached for Takeda to transfer the assets, marketing rights and, eventually, marketing authorization associated with a portfolio of diabetes products in Japan to fellow Japanese firm Teijin Pharma. 26 February 2021
Pharmaceutical
Danish diabetes care giant Novo Nordisk today announced plans to invest 500 million Danish kroner ($81.6 million) in expanding facilities at its production site in Måløv, Denmark. 25 February 2021
Pharmaceutical
US drugmaker Eli Lilly has announced trial results on tirzepatide, a once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist molecule that represents a new class of medicines being studied for the treatment of type 2 diabetes. 17 February 2021
Pharmaceutical
The European Commission (EC) has approved Ogluo (glucagon) injection for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. 15 February 2021
Pharmaceutical
New Phase III data from Novo Nordisk show that a once-weekly 2.4mg dose of semaglutide can have a dramatic impact on obesity, raising the prospect that the diabetes med could find a wider application in weight management. 11 February 2021
Pharmaceutical
Shares of Danish diabetes care giant Novo Nordisk were up 4.6% at 458.25 Danish kroner mid-morning, after the company announce financial results for the fourth quarter and full-year 2020. 3 February 2021
Pharmaceutical
Shares of US pharma major Eli Lilly were up 2.1% at $214.6 in pre-market trading, as the company reported financial results for the fourth-quarter and full year 2020. 30 January 2021
Pharmaceutical
Milan, Italy-based Enthera Pharmaceuticals today announced the final closing of its Series A financing, with a total financing of 35 million euros ($42.3 million). 28 January 2021
Generics
The European Investment Bank (EIB) will provide 20 million euros ($24.3 million) to finance the research, development and innovation program of Galenicum, a pharmaceutical company founded in Barcelona, Spain. 27 January 2021
Pharmaceutical
French pharma major Sanofi appears to have the opportunity to restore exclusive rights on insulin glargine in Russia as the Russian Intellectual Property Court has overturned a lower court decision to revoke Sanofi's patent for the drug, trade name Lantus, on the basis of a judicial claim submitted for the Russian drugmaker Geropharm a while ago, reports The Pharma Letter’s local correspondent. 26 January 2021
Pharmaceutical
The US Senate Finance Committee has released a new report detailing findings of its investigation into the role that market dynamics play in the pricing of insulins. 25 January 2021
Pharmaceutical
Novo Nordisk has sought a label expansion application from the US Food and Drug Administration (FDA) for the existing marketing authorization for Ozempic (semaglutide), a once-weekly glucagon-like peptide-1 (GLP-1) analogue, to introduce a new dose of 2mg. 21 January 2021
Generics
Viatris has disclosed that its oral finished-dose manufacturing facility in Indore, India, is subject to regulatory action from the US regulator, after an inspection earlier this year. 24 December 2024
Generics
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
Pharmaceutical
US pharma major Eli Lilly has recently announced a £279 million ($365.5 million) investment in the UK at the International Investment Summit in London. 19 December 2024
Pharmaceutical
The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking a significant milestone in its collaboration with US pharma major Eli Lilly. 18 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Biotechnology
Novavax has agreed to sell its manufacturing plant in the Czech Republic to Novo Nordisk for $200 million. 6 December 2024
Pharmaceutical
Novo Nordisk will reduce the US list prices of two insulin products, Tresiba (insulin degludec) and Fiasp (insulin aspart), by over 70% from 2026. 6 December 2024
Pharmaceutical
Eli Lilly has announced a $3 billion investment to expand its recently acquired manufacturing facility in Wisconsin, USA. 6 December 2024
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to establish a cutting-edge quality control laboratory in Hillerød, Denmark. 6 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
Hua Medicine has announced promising new clinical findings for its glucokinase activator dorzagliatin, presented at the China BioMed Innovation and Investment Conference. 2 December 2024
Pharmaceutical
Australia’s Department of Health and Aged Care has developed a new API (application programming interface) for the efficient distribution of the monthly Pharmaceutical Benefits Scheme (PBS) schedule data. 2 December 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Pharmaceutical
French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland bioproduction site, consolidating its role as a strategic platform dedicated to immunology. 15 November 2024
Pharmaceutical
Privately-held Montanan firm Microbion has announced promising findings from its Phase II study of pravibismane, a topical treatment aimed at addressing diabetic foot ulcer infections (DFI). 14 November 2024
Pharmaceutical
While sky high expectations for Eli Lilly’s tirzepatide have not yet been realized, more positive data add to a growing sense that the future could be as bright as imagined. 14 November 2024
Pharmaceutical
Germany’s Merck KGaA was trading 5% lower as Thursday’s trading day neared its end, after the company announced its third-quarter financial results and outlook for the rest of the year. 14 November 2024
Pharmaceutical
Anglo-Swedish drugmaker AstraZeneca beat analyst expectations with its third-quarter 2024 revenue and earnings figures. 12 November 2024
Biotechnology
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze